Opioid-sparing Analgesia
Opioid-sparing Analgesia - Related Videos
01:15
Opioid Analgesics: Synthetic and Semisynthetic Opioids
0 Views •
2024
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
07:42
Nerve-sparing Mid-urethral Obstruction (NeMO) in Female Small Rodents
0 Views •
Cited by 7 •
2017
Traditional modeling of partial bladder outlet obstruction in rodents is fraught with animal mortality. A denervation injury from dissection around the proximal urethra and bladder neck is also of major concern. We developed and evaluated a safe and reliable mid-urethral obstruction model, avoiding the shortcomings of the traditional model.
01:30
Spare Receptors
0 Views •
2023
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
01:22
Opioid Receptors: Overview
0 Views •
2024
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:25
Analgesia and Pain Management
0 Views •
2024
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
FAQs
The approach targets nociception through complementary mechanisms rather than relying on opioids alone. Acetaminophen, nonsteroidal anti-inflammatory drugs, local or regional anesthesia, and selected adjuvant medicines can contribute separate analgesic effects. Because these therapies work together, clinicians may achieve effective pain control with less opioid exposure, potentially reducing dose-related adverse effects while maintaining individualized treatment.
These therapies provide different components of a multimodal regimen. Acetaminophen and nonsteroidal anti-inflammatory drugs contribute non-opioid analgesia, while local or regional anesthesia addresses pain through a targeted anesthetic approach. Selected adjuvant medicines may add further complementary effects. Combining these options allows pain management to extend beyond a single opioid-centered strategy.
Lower exposure may reduce complications associated with opioid therapy, including sedation, respiratory depression, constipation, tolerance, and dependence. This matters particularly when effective pain relief must be balanced with recovery and function. Opioid-sparing analgesia addresses that balance by using other therapies to limit the opioid dose while continuing to support adequate individualized analgesia.
By limiting reliance on opioids while maintaining effective pain control, the strategy can reduce opioid-related effects that interfere with alertness, breathing, bowel function, or longer-term medication use. In perioperative and acute-care settings, this balance may help patients maintain function during recovery. The intended outcome is not eliminating analgesia, but achieving relief with less opioid burden.
A regimen combines non-opioid and anesthetic options according to the clinical need. Supported components include acetaminophen, nonsteroidal anti-inflammatory drugs, local or regional anesthesia, and selected adjuvant medicines, with opioids used at a reduced dose when needed for adequate relief. This multimodal structure gives clinicians several ways to support pain control rather than depending on one therapy.
It is particularly relevant in perioperative and acute-care settings, where effective pain control must coexist with recovery and preserved function. The approach can reduce the opioid dose needed for adequate analgesia and may lessen opioid-related adverse effects. Its value lies in individualized pain management that combines complementary therapies while retaining sufficient relief for the clinical situation.